J

Johnson & Johnson

Makes prescription drugs and medical devices

Staff Digital Embedded Software Engineer

Full-TimeUpdated on 10/24/2026Deadline 11/9/26
$109k - $174.9k+ Annual performance bonus + Long-term incentive program
Senior, Expert
Bachelor's, Master's, PhD
Raynham, MA, USA+1 moreMore locations: Palm Beach Gardens, FL, USA
HybridHybrid work in Raynham, MA or Palm Beach Gardens, FL; travel up to 10%, including international.
Software EngineeringEmbedded Engineering

About the job

Requirements
  • A Bachelor's degree in Computer Engineering, Computer Science, Electrical Engineering, or a related technical discipline with 8+ years of relevant experience; a Master's degree with 6+ years; or a PhD with 4+ years.
  • Strong software development experience in C and C++.
  • Experience developing software using Python for automation, testing, tooling, or product features.
  • Experience developing software for embedded microcontroller systems.
  • Experience with bare-metal and real-time operating system (RTOS)-based embedded systems development.
  • Experience with embedded Linux development, including device drivers, services, and application-level software.
  • Experience with board bring-up, hardware/software integration, and low-level debugging.
  • Experience with communication protocols including SPI, I2C, UART, CAN, USB, Ethernet, TCP/IP, and UDP.
  • Experience delivering commercial products through a complete product development lifecycle.
  • Strong understanding of software engineering principles, including source control, code reviews, configuration management, and software release processes.
  • Experience developing software under regulated design control environments.
  • Strong written and verbal communication skills with the ability to collaborate across multidisciplinary teams.
  • Experience managing external software development partners and outsourced engineering activities.
  • Willingness to work in medical environments such as cadaver labs and operating rooms.
  • Experience developing software for FDA-regulated medical devices.
  • Knowledge of IEC 62304 medical device software lifecycle processes.
Responsibilities
  • Serve as the Software Technical Lead for strategic capital equipment and power tool development programs, with responsibility for software architecture, technical direction, and delivery execution.
  • Lead embedded software architecture, design, development, integration, and verification for safety-critical medical device applications.
  • Act as the primary software subject matter expert within a cross-functional development team, partnering closely with systems, electrical, mechanical, cybersecurity, quality, and regulatory engineering functions.
  • Develop production software in C/C++ and Python while providing hands-on technical leadership throughout development activities.
  • Translate product and system requirements into scalable software architectures, detailed designs, and executable development plans.
  • Drive all phases of the software development lifecycle, including requirements definition, architecture, implementation, unit testing, integration, verification, validation support, release, and post-market support.
  • Lead hardware/software integration activities, board bring-up, and system-level problem solving using data-driven root cause analysis techniques.
  • Direct, prioritize, and review software work performed by external development partners and vendors, ensuring alignment with project objectives, quality expectations, and regulatory requirements.
  • Delegate software development activities while maintaining overall accountability for software quality, technical execution, and delivery timelines.
  • Evaluate technical alternatives, identify risks, and make architecture and implementation decisions that balance performance, maintainability, cybersecurity, and regulatory compliance.
  • Champion software engineering procedures including code reviews, source control, automated testing, documentation, and design controls.
  • Provide technical mentorship and guidance to internal and external software contributors.
  • Serve as the key software representative during design reviews, risk management activities, regulatory submissions, and senior leadership reviews.
  • Work with design engineers, surgeons, manufacturing, quality, regulatory affairs, product directors, and other team members to design and develop software for new and existing electromechanical devices and associated capital equipment.
  • Plan assigned tasks and complete software development project deliverables.
  • Follow all laws and policies that apply to the role and maintain professional, ethical, and compliance standards.
Desired Qualifications
  • Knowledge of ISO 14971 risk management principles.
  • Experience supporting software cybersecurity activities for connected medical devices.
  • Hands-on experience with STMicroelectronics and/or Texas Instruments microcontroller platforms.
  • Experience with bootloaders, firmware update mechanisms, and secure software deployment.
  • Understanding of software architecture methodologies, Unified Modeling Language (UML), and design patterns.
  • Experience working with Agile development methodologies and DevOps practices.
  • Familiarity with continuous integration and continuous delivery (CI/CD) pipelines, automated testing frameworks, and static analysis tools.
  • Ability to read and interpret electronic schematics and interface specifications.
  • Experience with motor control, power tools, surgical capital equipment, imaging systems, or connected medical devices.
  • Knowledge of developing Windows applications.
  • Proven experience in the design and development of applications and drivers on Linux.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.